Phenotypic and functional characterization of herpes simplex virus glycoprotein B epitope-specific effector and memory CD8+ T cells from symptomatic and asymptomatic individuals with ocular herpes

Journal of Virology

Volumn 89, Issue 7, 2015, Pages 3776-3792

  Khan, Arif A ^a   Srivastava, Ruchi ^a   Spencer, Doran ^a   Garg, Sumit ^a   Fremgen, Daniel ^a   Vahed, Hawa ^a   Lopes, Patricia P ^a   Pham, Thanh T ^a   Hewett, Charlie ^a   Kuang, Jasmine ^a   Ong, Nicolas ^a   Huang, Lei ^a   Scarfone, Vanessa M ^b   Nesburn, Anthony B ^a   Wechsler, Steven L ^a   BenMohamed, Lbachir ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN B; GRANZYME B; HLA A ANTIGEN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; PERFORIN; GLYCOPROTEIN B, SIMPLEXVIRUS; VIRUS ENVELOPE PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELL PROTECTION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HERPES SIMPLEX VIRUS 1; HERPES ZOSTER OPHTHALMICUS; HUMAN; HUMAN CELL; IMMUNIZATION; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS CHARACTERIZATION; ADOLESCENT; ANIMAL; ASYMPTOMATIC DISEASE; CHEMISTRY; HERPES SIMPLEX KERATITIS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; YOUNG ADULT;

HUMAN HERPESVIRUS 1; MUS; MUS MUSCULUS; SIMPLEXVIRUS;

ADOLESCENT; ADULT; AGED; ANIMALS; ASYMPTOMATIC DISEASES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; KERATITIS, HERPETIC; MALE; MIDDLE AGED; T-LYMPHOCYTE SUBSETS; VIRAL ENVELOPE PROTEINS; YOUNG ADULT;

EID: 84924777929     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03419-14     Document Type: Article

References (82)

1. Srivastava R, Khan AA, Spencer D, Vahed H, Thai NTU, Lopes PP, Wang C, Pham TT, Scarfone VM, Jester JV, Nesburn AB, Wechsler SL, BenMohamed L. 23 January 2015. HLA-A02:01-restricted epitopes identified from the herpes simplex virus tegument protein VP11/12 preferentially recall polyfunctional effector memory CD8+ T cells from seropositive asymptomatic individuals and protect "humanized" HLA-A*02:01 transgenic mice against ocular herpes. J Immunol http://dx.doi.org/10.4049/jimmunol.1402606.
2. Kuo T, Wang C, Badakhshan T, Chilukuri S, BenMohamed L. 2014. The challenges and opportunities for the development of a T-cell epitopebased herpes simplex vaccine. Vaccine 32:6733-6745. http://dx.doi.org/10.1016/j.vaccine.2014.
3. Samandary S, Kridane-Miledi H, Sandoval JS, Choudhury Z, Langa-Vives F, Spencer D, Chentoufi AA, Lemonnier FA, BenMohamed L. 2014. Associations of HLA-A, HLA-B and HLA-C allele frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of a universal CD8+T-cell epitope-based vaccine. Hum Immunol 75:715-729. http://dx.doi.org/10.1016/j.humimm.2014.04.016.
4. Zhang X, Dervillez X, Chentoufi AA, Badakhshan T, Bettahi I, Ben-Mohamed L. 2012. Targeting the genital tract mucosa with a lipopeptide/recombinant adenovirus prime/boost vaccine induces potent and long-lasting CD8+ T cell immunity against herpes: importance of MyD88. J Immunol 189:4496-4509. http://dx.doi.org/10.4049/jimmunol.1201121.
5. Chentoufi AA, Dasgupta G, Christensen ND, Hu J, Choudhury ZS, Azeem A, Jester JV, Nesburn AB, Wechsler SL, BenMohamed L. 2010. A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes. J Immunol 184:2561-2571. http://dx.doi.org/10.4049/jimmunol.0902322.
6. Chentoufi AA, Zhang X, Lamberth K, Dasgupta G, Bettahi I, Nguyen A, Wu M, Zhu X, Mohebbi A, Buus S, Wechsler SL, Nesburn AB, Ben-Mohamed L. 2008. HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J Immunol 180:426-437. http://dx.doi.org/10.4049/jimmunol.180.1.426.
7. Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE. 1999. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 341:1432-1438.
8. Dasgupta G, BenMohamed L. 2011. Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cellepitopes-based immunotherapeutic vaccine candidates?. Vaccine 29: 5824-5836. http://dx.doi.org/10.1016/j.vaccine.2011.06.083.
9. Chentoufi AA, Binder NR, Berka N, Durand G, Nguyen A, Bettahi I, Maillere B, BenMohamed L. 2008. Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B. J Virol 82:11792-11802. http://dx.doi.org/10.1128/JVI.00692-08.
10. BenMohamed L, Bertrand G, McNamara CD, Gras-Masse H, Hammer J, Wechsler SL, Nesburn AB. 2003. Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J Virol 77:9463-9473. http://dx.doi.org/10.1128/JVI.77.17.9463-9473.2003.
11. Zhang X, Issagholian A, Berg EA, Fishman JB, Nesburn AB, BenMohamed L. 2005. Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+Tc1 responses and protect against ocular infection. J Virol 79:15289-15301. http://dx.doi.org/10.1128/JVI.79.24.15289-15301.2005.
12. Nesburn AB, Bettahi I, Zhang X, Zhu X, Chamberlain W, Afifi RE, Wechsler SL, BenMohamed L. 2006. Topical/mucosal delivery of subunit vaccines that stimulate the ocular mucosal immune system. Ocul Surf 4:178-187. http://dx.doi.org/10.1016/S1542-0124(12)70164-7.
13. Dervillez X, Qureshi H, Chentoufi AA, Khan AA, Kritzer E, Yu DC, Diaz OR, Gottimukkala C, Kalantari M, Villacres MC, Scarfone VM, McKinney DM, Sidney J, Sette A, Nesburn AB, Wechsler SL, BenMohamed L. 2013. Asymptomatic HLA-A*02:01-restricted epitopes from herpes simplex virus glycoprotein B preferentially recall polyfunctional CD8+ T cells from seropositive asymptomatic individuals and protect HLA transgenic mice against ocular herpes. J Immunol 191:5124-5138. http://dx.doi.org/10.4049/jimmunol.1301415.
14. Banerjee K, Biswas PS, Rouse BT. 2005. Elucidating the protective and pathologic T cell species in the virus-induced corneal immunoinflammatory condition herpetic stromal keratitis. J Leukoc Biol 77:24-32. http://dx.doi.org/10.1189/jlb.0904486.
15. Stuart PM, Summers B, Morris JE, Morrison LA, Leib DA. 2004. CD8(+) T cells control corneal disease following ocular infection with herpes simplex virus type 1. J Gen Virol 85:2055-2063. http://dx.doi.org/10.1099/vir.0.80049-0.
16. Banerjee K, Deshpande S, Zheng M, Kumaraguru U, Schoenberger SP, Rouse BT. 2002. Herpetic stromal keratitis in the absence of viral antigen recognition. Cell Immunol 219:108-118. http://dx.doi.org/10.1016/S0008-8749(02)00601-9.
17. Bouley DM, Kanangat S, Wire W, Rouse BT. 1995. Characterization of herpes simplex virus type-1 infection and herpetic stromal keratitis development in IFN-gamma knockout mice. J Immunol 155:3964-3971.
18. Babu JS, Thomas J, Kanangat S, Morrison LA, Knipe DM, Rouse BT. 1996. Viral replication is required for induction of ocular immunopathology by herpes simplex virus. J Virol 70:101-107.
19. Zarling JM, Moran PA, Brewer L, Ashley R, Corey L. 1988. Herpes simplex virus (HSV)-specific proliferative and cytotoxic T-cell responses in humans immunized with an HSV type 2 glycoprotein subunit vaccine. J Virol 62:4481-4485.
20. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, Tyring S, Aoki FY, Slaoui M, Denis M, Vandepapeliere P, Dubin G. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 347:1652-1661. http://dx.doi.org/10.1056/NEJMoa011915.
21. Zhu X, Ramos TV, Gras-Masse H, Kaplan BE, BenMohamed L. 2004. Lipopeptide epitopes extended by anNe-palmitoyl lysine moiety increases uptake and maturation of dendritic cell through a Toll-like receptor 2 pathway and triggers a Th1-dependent protective immunity. Eur J Immunol 34:1142-1149. http://dx.doi.org/10.1002/eji.200425166.
22. Blaney JE, Jr, Nobusawa E, Brehm MA, Bonneau RH, Mylin LM, Fu TM, Kawaoka Y, Tevethia SS. 1998. Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity. J Virol 72:9567-9574.
23. St Leger AJ, Peters B, Sidney J, Sette A, Hendricks RL. 2011. Defining the herpes simplex virus-specific CD8+T cell repertoire in C57BL/6 mice. J Immunol 186:3927-3933. http://dx.doi.org/10.4049/jimmunol.1003735.
24. Suvas S, Azkur AK, Rouse BT. 2006. Qa-1b and CD94-NKG2a interaction regulate cytolytic activity of herpes simplex virus-specific memory CD8+ T cells in the latently infected trigeminal ganglia. J Immunol 176: 1703-1711. http://dx.doi.org/10.4049/jimmunol.176.3.1703.
25. Chentoufi AA, BenMohamed L, Van De Perre P, Ashkar AA. 2012. Immunity to ocular and genital herpes simplex viruses infections. Clin Dev Immunol 2012:732546. http://dx.doi.org/10.1155/2012/732546.
26. Khan AA, Srivastava R, Lopes PP, Wang C, Pham TT, Cochrane J, Thai NT, Gutierrez L, BenMohamed L. 2014. Asymptomatic memory CD8 T cells: from development and regulation to consideration for human vaccines and immunotherapeutics. Hum Vaccin Immunother 10:945-963. http://dx.doi.org/10.4161/hv.27762.
27. Romero P, Zippelius A, Kurth I, Pittet MJ, Touvrey C, Iancu EM, Corthesy P, Devevre E, Speiser DE, Rufer N. 2007. Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J Immunol 178:4112-4119. http://dx.doi.org/10.4049/jimmunol.178.7.4112.
28. Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. 2009. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol 10:524-530. http://dx.doi.org/10.1038/ni.1718.
29. Jiang X, Clark RA, Liu L, Wagers AJ, Fuhlbrigge RC, Kupper TS. 2012. Skin infection generates non-migratory memory CD8+T(RM) cells providing global skin immunity. Nature 483:227-231. http://dx.doi.org/10.1038/nature10851.
30. Shin H, Iwasaki A. 2012. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 491:463-467. http://dx.doi.org/10.1038/nature11522.
31. Osorio Y, Mott KR, Jabbar AM, Moreno A, Foster TP, Kousoulas KG, Ghiasi H. 2007. Epitope mapping of HSV-1 glycoprotein K (gK) reveals a T cell epitope located within the signal domain of gK. Virus Res 128:71-80. http://dx.doi.org/10.1016/j.virusres.2007.04.007.
32. Mott KR, Chentoufi AA, Carpenter D, BenMohamed L, Wechsler SL, Ghiasi H. 2009. The role of a glycoprotein K (gK) CD8+T-cell epitope of herpes simplex virus on virus replication and pathogenicity. Invest Ophthalmol Vis Sci 50:2903-2912. http://dx.doi.org/10.1167/iovs.08-2957.
33. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA. 2003. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281:65-78. http://dx.doi.org/10.1016/S0022-1759(03)00265-5.
34. BenMohamed L, Krishnan R, Auge C, Primus JF, Diamond DJ. 2002. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology 106:113-121. http://dx.doi.org/10.1046/j.1365-2567.2002.01396.x.
35. BenMohamed L, Krishnan R, Longmate J, Auge C, Low L, Primus J, Diamond DJ. 2000. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response. Hum Immunol 61:764-779. http://dx.doi.org/10.1016/S0198-8859(00)00139-7.
36. Boucherma R, Kridane-Miledi H, Bouziat R, Rasmussen M, Gatard T, Langa-Vives F, Lemercier B, Lim A, Berard M, Benmohamed L, Buus S, Rooke R, Lemonnier FA. 2013. HLA-A*01:03, HLA-A*24:02, HLA-B*08: 01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 monochain transgenic/H-2 class I null mice: novel versatile preclinical models of human T cell responses. J Immunol 191:583-593. http://dx.doi.org/10.4049/jimmunol.1300483.
37. Zhang X, Chentoufi AA, Dasgupta G, Nesburn AB, Wu M, Zhu X, Carpenter D, Wechsler SL, You S, BenMohamed L. 2009. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol 2:129-143. http://dx.doi.org/10.1038/mi.2008.81.
38. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708-712. http://dx.doi.org/10.1038/44385.
39. Joshi NS, Kaech SM. 2008. Effector CD8 T cell development: a balancing act between memory cell potential and terminal differentiation. J Immunol 180:1309-1315. http://dx.doi.org/10.4049/jimmunol.180.3.1309.
40. Channappanavar R, Twardy BS, Suvas S. 2012. Blocking of PDL-1 interaction enhances primary and secondary CD8 T cell response to herpes simplex virus-1 infection. PLoS One 7:e39757. http://dx.doi.org/10.1371/journal.pone.0039757.
41. Mott KR, Bresee CJ, Allen SJ, BenMohamed L, Wechsler SL, Ghiasi H. 2009. Level of herpes simplex virus type 1 latency correlates with severity of corneal scarring and exhaustion of CD8+ T cells in trigeminal ganglia of latently infected mice. J Virol 83:2246-2254. http://dx.doi.org/10.1128/JVI.02234-08.
42. St Leger AJ, Jeon S, Hendricks RL. 2013. Broadening the repertoire of functional herpes simplex virus type 1-specific CD8+T cells reduces viral reactivation from latency in sensory ganglia. J Immunol 191:2258-2265. http://dx.doi.org/10.4049/jimmunol.1300585.
43. Knickelbein JE, Khanna KM, Yee MB, Baty CJ, Kinchington PR, Hendricks RL. 2008. Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency. Science 322:268-271. http://dx.doi.org/10.1126/science.1164164.
44. Iancu EM, Corthesy P, Baumgaertner P, Devevre E, Voelter V, Romero P, Speiser DE, Rufer N. 2009. Clonotype selection and composition of human CD8 T cells specific for persistent herpes viruses varies with differentiation but is stable over time. J Immunol 183:319-331. http://dx.doi.org/10.4049/jimmunol.0803647.
45. Hopken UE, Winter S, Achtman AH, Kruger K, Lipp M. 2010. CCR7 regulates lymphocyte egress and recirculation through body cavities. J Leukoc Biol 87:671-682. http://dx.doi.org/10.1189/jlb.0709505.
46. Hikono H, Kohlmeier JE, Takamura S, Wittmer ST, Roberts AD, Woodland DL. 2007. Activation phenotype, rather than central-or effector-memory phenotype, predicts the recall efficacy of memory CD8+ T cells. J Exp Med 204:1625-1636. http://dx.doi.org/10.1084/jem.20070322.
47. Ouwendijk WJ, Geluk A, Smits SL, Getu S, Osterhaus AD, Verjans GM. 2014. Functional characterization of ocular-derived human alphaherpesvirus cross-reactive CD4 T cells. J Immunol 192:3730-3739. http://dx.doi.org/10.4049/jimmunol.1302307.
48. van Velzen M, Jing L, Osterhaus AD, Sette A, Koelle DM, Verjans GM. 2013. Local CD4 and CD8 T-cell reactivity to HSV-1 antigens documents broad viral protein expression and immune competence in latently infected human trigeminal ganglia. PLoS Pathog 9:e1003547. http://dx.doi.org/10.1371/journal.ppat.1003547.
49. van Velzen M, Missotten T, van Loenen FB, Meesters RJ, Luider TM, Baarsma GS, Osterhaus AD, Verjans GM. 2013. Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients. J Clin Virol 57:215-221. http://dx.doi.org/10.1016/j.jcv.2013.03.014.
50. Allen SJ, Hamrah P, Gate D, Mott KR, Mantopoulos D, Zheng L, Town T, Jones C, von Andrian UH, Freeman GJ, Sharpe AH, BenMohamed L, Ahmed R, Wechsler SL, Ghiasi H. 2011. The role of LAT in increased CD8+ T cell exhaustion in trigeminal ganglia of mice latently infected with herpes simplex virus 1. J Virol 85:4184-4197. http://dx.doi.org/10.1128/JVI.02290-10.
51. Arbusow V, Derfuss T, Held K, Himmelein S, Strupp M, Gurkov R, Brandt T, Theil D. 2010. Latency of herpes simplex virus type-1 in human geniculate and vestibular ganglia is associated with infiltration of CD8+T cells. J Med Virol 82:1917-1920. http://dx.doi.org/10.1002/jmv.21904.
52. Chentoufi AA, BenMohamed L. 2010. Future viral vectors for the delivery of asymptomatic herpes epitope-based immunotherapeutic vaccines. Future Virol 5:525-528. http://dx.doi.org/10.2217/fvl.10.44.
53. Held K, Eiglmeier I, Himmelein S, Sinicina I, Brandt T, Theil D, Dornmair K, Derfuss T. 2012. Clonal expansions of CD8(+) T cells in latently HSV-1-infected human trigeminal ganglia. J Neurovirol 18:62-68. http://dx.doi.org/10.1007/s13365-011-0067-9.
54. Zhu J, Hladik F, Woodward A, Klock A, Peng T, Johnston C, Remington M, Magaret A, Koelle DM, Wald A, Corey L. 2009. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 15:886-892. http://dx.doi.org/10.1038/nm.2006.
55. Zhu J, Koelle DM, Cao J, Vazquez J, Huang ML, Hladik F, Wald A, Corey L. 2007. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 204:595-603. http://dx.doi.org/10.1084/jem.20061792.
56. Divito SJ, Hendricks RL. 2008. Activated inflammatory infiltrate in HSV-1-infected corneas without herpes stromal keratitis. Invest Ophthalmol Vis Sci 49:1488-1495. http://dx.doi.org/10.1167/iovs.07-1107.
57. Cruz-Guilloty F, Pipkin ME, Djuretic IM, Levanon D, Lotem J, Lichtenheld MG, Groner Y, Rao A. 2009. Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. J Exp Med 206:51-59. http://dx.doi.org/10.1084/jem.20081242.
58. Joshi NS, Cui W, Dominguez CX, Chen JH, Hand TW, Kaech SM. 2011. Increased numbers of preexisting memory CD8 T cells and decreased T-bet expression can restrain terminal differentiation of secondary effector and memory CD8 T cells. J Immunol 187:4068-4076. http://dx.doi.org/10.4049/jimmunol.1002145.
59. Cannarile MA, Lind NA, Rivera R, Sheridan AD, Camfield KA, Wu BB, Cheung KP, Ding Z, Goldrath AW. 2006. Transcriptional regulator Id2 mediates CD8+ T cell immunity. Nat Immunol 7:1317-1325. http://dx.doi.org/10.1038/ni1403.
60. Hufner K, Horn A, Derfuss T, Glon C, Sinicina I, Arbusow V, Strupp M, Brandt T, Theil D. 2009. Fewer latent herpes simplex virus type 1 and cytotoxic T cells occur in the ophthalmic division than in the maxillary and mandibular divisions of the human trigeminal ganglion and nerve. J Virol 83:3696-3703. http://dx.doi.org/10.1128/JVI.02464-08.
61. Jung YW, Rutishauser RL, Joshi NS, Haberman AM, Kaech SM. 2010. Differential localization of effector and memory CD8 T cell subsets in lymphoid organs during acute viral infection. J Immunol 185:5315-5325. http://dx.doi.org/10.4049/jimmunol.1001948.
62. Chandele A, Joshi NS, Zhu J, Paul WE, Leonard WJ, Kaech SM. 2008. Formation of IL-7Ralphahigh and IL-7Ralphalow CD8 T cells during infection is regulated by the opposing functions of GABPalpha and Gfi-1. J Immunol 180:5309-5319. http://dx.doi.org/10.4049/jimmunol.180.8.5309.
63. Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, Hagman J, Gapin L, Kaech SM. 2007. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 27:281-295. http://dx.doi.org/10.1016/j.immuni.2007.07.010.
64. Mackay LK, Rahimpour A, Ma JZ, Collins N, Stock AT, Hafon ML, Vega-Ramos J, Lauzurica P, Mueller SN, Stefanovic T, Tscharke DC, Heath WR, Inouye M, Carbone FR, Gebhardt T. 2013. The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin. Nat Immunol 14:1294-1301. http://dx.doi.org/10.1038/ni.2744.
65. Gebhardt T, Whitney PG, Zaid A, Mackay LK, Brooks AG, Heath WR, Carbone FR, Mueller SN. 2011. Different patterns of peripheral migration by memory CD4+and CD8+T cells. Nature 477:216-219. http://dx.doi.org/10.1038/nature10339.
66. Belz GT, Wilson NS, Smith CM, Mount AM, Carbone FR, Heath WR. 2006. Bone marrow-derived cells expand memory CD8+ T cells in response to viral infections of the lung and skin. Eur J Immunol 36:327-335. http://dx.doi.org/10.1002/eji.200535432.
67. Marzo AL, Yagita H, Lefrancois L. 2007. Cutting edge: migration to nonlymphoid tissues results in functional conversion of central to effector memory CD8 T cells. J Immunol 179:36-40. http://dx.doi.org/10.4049/jimmunol.179.1.36.
68. Hogan RJ, Cauley LS, Ely KH, Cookenham T, Roberts AD, Brennan JW, Monard S, Woodland DL. 2002. Long-term maintenance of virusspecific effector memory CD8+ T cells in the lung airways depends on proliferation. J Immunol 169:4976-4981. http://dx.doi.org/10.4049/jimmunol.169.9.4976.
69. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R, von Andrian UH, Ahmed R. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 4:225-234. http://dx.doi.org/10.1038/ni889.
70. Plunkett FJ, Franzese O, Belaramani LL, Fletcher JM, Gilmour KC, Sharifi R, Khan N, Hislop AD, Cara A, Salmon M, Gaspar HB, Rustin MH, Webster D, Akbar AN. 2005. The impact of telomere erosion on memory CD8+T cells in patients with X-linked lymphoproliferative syndrome. Mech Ageing Dev 126:855-865. http://dx.doi.org/10.1016/j.mad.2005.03.006.
71. Akbar AN, Fletcher JM. 2005. Memory T cell homeostasis and senescence during aging. Curr Opin Immunol 17:480-485. http://dx.doi.org/10.1016/j.coi.2005.07.019.
72. Dudek TE, Torres-Lopez E, Crumpacker C, Knipe DM. 2011. Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa. J Infect Dis 203:1434-1441. http://dx.doi.org/10.1093/infdis/jir047.
73. Belshe PB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, Gorfinkel I, Morrow RLA, Ewell MG, Stokes-Riner A, Dubin G, Heineman TC, Schulte JM, Deal CD. 2012. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 366:34-43. http://dx.doi.org/10.1056/NEJMoa1103151.
74. Knipe DM, Corey L, Cohen JI, Deal CD. 2014. Summary and recommendations from a National Institute of Allergy and Infectious Diseases (NIAID) workshop on "Next Generation Herpes Simplex Virus Vaccines." Vaccine 32:1561-1562. http://dx.doi.org/10.1016/j.vaccine.2014.01.052.
75. El-Awar N, Lee JH, Tarsitani C, Terasaki PI. 2007. HLA class I epitopes: recognition of binding sites by mAbs or eluted alloantibody confirmed with single recombinant antigens. Hum Immunol 68:170-180. http://dx.doi.org/10.1016/j.humimm.2006.11.006.
76. Pekiner FN, Aytugar E, Demirel GY, Borahan MO. 2013. HLA-A, B (class I) and HLA-DR, DQ (class II) antigens in Turkish patients with recurrent aphthous ulceration and Behcet's disease. Med Princ Pract 22: 464-468. http://dx.doi.org/10.1159/000348366.
77. Castelli EC, Gil DS, Veiga LC, de Camargo JL. 2005. Typing class I HLA-A gene using a nested PCR-RFLP procedure. Braz J Med Biol Res 38:837-842. http://dx.doi.org/10.1590/S0100-879X2005000600004.
78. Sidney J, Southwood S, Mann DL, Fernandez-Vina MA, Newman MJ, Sette A. 2001. Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. Hum Immunol 62: 1200-1216. http://dx.doi.org/10.1016/S0198-8859(01)00319-6.
79. BenMohamed L, Belkaid Y, Loing E, Brahimi K, Gras-Masse H, Druilhe P. 2002. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur J Immunol 32:2274-2281. http://dx.doi.org/10.1002/1521-4141(200208)32:8<2274::AID-IMMU2274>3.0.CO;2-C.
80. BenMohamed L, Wechsler SL, Nesburn AB. 2002. Lipopeptide vaccines-yesterday, today, and tomorrow. Lancet Infect Dis 2:425-431. http://dx.doi.org/10.1016/S1473-3099(02)00318-3.
81. Sette A, Newman M, Livingston B, McKinney D, Sidney J, Ishioka G, Tangri S, Alexander J, Fikes J, Chesnut R. 2002. Optimizing vaccine design for cellular processing, MHC binding and TCR recognition. Tissue Antigens 59:443-451. http://dx.doi.org/10.1034/j.1399-0039.2002.590601.x.
82. Bettahi I, Nesburn AB, Yoon S, Zhang X, Mohebbi A, Sue V, Vanderberg A, Wechsler SL, BenMohamed L. 2007. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines. Invest Ophthalmol Vis Sci 48:4643-4653. http://dx.doi.org/10.1167/iovs.07-0356.